Home Cart Sign in  
Chemical Structure| 69408-81-7 Chemical Structure| 69408-81-7

Structure of Amonafide
CAS No.: 69408-81-7

Chemical Structure| 69408-81-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Amonafide produces protein-associated DNA-strand breaks through a topoisomerase II-mediated reaction, but does not produce topoisomerase I-mediated DNA cleavage.

Synonyms: AS1413; Benzisoquinolinedione; Xanafide

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Amonafide

CAS No. :69408-81-7
Formula : C16H17N3O2
M.W : 283.33
SMILES Code : O=C(C1=CC(N)=CC2=CC=CC3=C21)N(C3=O)CCN(C)C
Synonyms :
AS1413; Benzisoquinolinedione; Xanafide
MDL No. :MFCD00866438
InChI Key :UPALIKSFLSVKIS-UHFFFAOYSA-N
Pubchem ID :50515

Safety of Amonafide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Amonafide

DNA

Isoform Comparison

Biological Activity

Target
  • Topo II

In Vitro:

Cell Line
Concentration Treated Time Description References
P388 cells 1-25 μM 30 minutes To study the stimulation of DNA cleavage by Amonafide in P388 cells, it was found that Amonafide mainly stimulated DNA cleavage at a single site in pBR322 DNA, with the cleavage level increasing with dose, reaching a maximum of 60%. PMC306658
PC-3 cells 1 μM 5 days dramatically decreased the expression of the proangiogenic CXCL chemokines PMC2386542
MCF-7 5 µM 48 hours Xanafide exhibited a lower TGI concentration in MCF-7 cells, showing strong anti-proliferative effects. PMC2359668
SKBR-3 6 µM 48 hours Xanafide exhibited comparable TGI concentrations to paclitaxel and vinorelbine in SKBR-3 cells. PMC2359668
T47D 20 µM 48 hours Xanafide did not induce any complete growth inhibition in T47D cells. PMC2359668
AGS 5 μM 24 hours To evaluate the effects of these compounds on cell proliferation and apoptosis. AMN, AN, and MEAN all significantly increased DNA content in AGS cells, indicating that these compounds cause G2 arrest. PMC3084622
Huh7 5 μM and 10 μM 24 hours To evaluate the effects of AMN, AN, and MEAN on apoptosis in Huh7 cells. AMN and MEAN significantly increased apoptosis at 5 and 10μM, and were more potent than AN. PMC3084622
HepG2 2 μM Overnight To assess the effects of AMN, AN, and MEAN on gene expression in HepG2 cells through gene array analysis. MEAN, AMN, and AN significantly altered the expression levels of 347, 199, and 178 transcripts, respectively, indicating that these compounds act through similar mechanisms. PMC6802659

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
nude mice PC-3 and DU-145 prostate cancer xenograft models intravenous 25 mg/kg 3 times per week for 3 weeks significantly increased survival and demonstrated antiangiogenic properties PMC2386542
NCr nude mice MCF-7 and MDA-MB-231 breast cancer cell models Intraperitoneal injection 10 mg/kg three times a week for 6 consecutive weeks Xanafide reduced tumor cell growth by 41% and 46% in MCF-7 and MDA-MB-231 cells, respectively, showing strong anti-tumor activity. PMC2359668
Nude mice HepG2 xenograft model Intraperitoneal injection 100 mg/kg/day 10 consecutive days To evaluate the antitumor efficacy and tolerance of AMN, AN, and MEAN in the HepG2 xenograft model. AMN was most effective at 50 and 100 μmol/kg, while MEAN was equally effective at 200 μmol/kg and better tolerated. PMC3084622
nude mice orthotopic human prostate cancer PC-3 and DU-145 xenograft models intravenous (i.v.) 10 mg/kg Single dose significantly increased survival and revealed antiangiogenic properties PMC2386542

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00273884 Acute Myeloid Leukemia Phase 2 Completed - -
NCT00074100 Breast Cancer Phase 2 Completed - United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Less <<
NCT00087854 Prostate Cancer Phase 1 Phase 2 Completed - United States, California ... More >> USC Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 United States, Maryland Cancer Center at John Hopkins Baltimore, Maryland, United States, 21231 United States, Missouri Barnard Cancer Center St.Louis, Missouri, United States, 63110 United States, New Jersey Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08901 United States, New York Herbert Irving Cancer Center New York, New York, United States, 10032-3789 United States, Ohio The Cleveland Clinic Cleveland, Ohio, United States, 44195 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111-2497 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 Less <<
NCT01066494 Acute Myeloid Leukemia Phase 2 Unknown January 2011 Georgia ... More >> Institute of Haematology and Transfusiology Tbilisi, Georgia, 0177 Medulla - Chemotherapy and Immunotherapy Clinic Tbilisi, Georgia, 0186 Hema - Haematology and Chemotherapy Clinic Tbilisi, Georgia Ukraine Institure of URgent adn Recovery Surgery n.a. V.K. gusaka of Academy Medical Science of Ukraine Donetsk, Ukraine, 83045 Kyiv bone Marrow Transplantation Centre Kiev, Ukraine, 03115 Vinnytsya Regional clinical Hospital Vinnytsya, Ukraine, 21018 Less <<
NCT00715637 Secondary Acute Myeloid Leukem... More >>ia (Secondary AML, sAML) Less << Phase 3 Unknown - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.53mL

0.71mL

0.35mL

17.65mL

3.53mL

1.76mL

35.29mL

7.06mL

3.53mL

References

 

Historical Records

Categories